AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15710069 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day + UDCA 300 mg/day
Number of subjects: 48
Study 15710069 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day
Number of subjects: 48
Study 11098961 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric feeding (1 L containing 70 g protein and 1000 kcal)
Number of subjects: 40
Study 11098961 — intervention group
Group type: COMPARATOR
Intervention: Standard weight‐based regimen (25 kcal and 1.5 g protein/kg dry weight)
Number of subjects: 40
Study 11098961 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric feeding
Number of subjects: 40
Study 11098961 — intervention group
Group type: COMPARATOR
Intervention: Standard weight‐based regimen
Number of subjects: 40
Study 9311395 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil and propofol
Number of subjects: 80
Study 9311395 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil, thiopental and suxamethonium
Number of subjects: 80
Study 8159594 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine in chocolate wafer
Number of subjects: 7
Study 8159594 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclosporine mixed with Isocal
Number of subjects: 7
Study 8159594 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclosporine
Number of subjects: 7
Study 2851016 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparine 20 mg
Number of subjects: 12
Study 2851016 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparine 40 mg
Number of subjects: 12
Study 2851016 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparine 60 mg
Number of subjects: 12
Study 2851016 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparine 80 mg
Number of subjects: 12
Study 31132209 — intervention group
Group type: COMPARATOR
Intervention: Game-based flexibility training
Number of subjects: 153
Study 31132209 — intervention group
Group type: COMPARATOR
Intervention: Game-based inhibition training
Number of subjects: 153
Study 31132209 — intervention group
Group type: COMPARATOR
Intervention: Standard training groups
Number of subjects: 153
Study 31132209 — intervention group
Group type: COMPARATOR
Intervention: All training groups
Number of subjects: 153
Study 31132209 — intervention group
Group type: COMPARATOR
Intervention: Game-based and standard training regimens
Number of subjects: 153
Study 29890381 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (cACB)
Number of subjects: 165
Study 29890381 — intervention group
Group type: COMPARATOR
Intervention: Sham catheter
Number of subjects: 165
Study 28324706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU)
Number of subjects: 124
Study 28324706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU) with positive emotion inductions
Number of subjects: 124
Study 28324706 — intervention group
Group type: COMPARATOR
Intervention: Positive emotion inductions (social warmth, pride, neutral)
Number of subjects: 124
Study 27367855 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 μg Se as selenized yeast) and Coenzyme Q10 (200 mg) supplementation for four years
Number of subjects: 668
Study 27367855 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 668
Study 23947538 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory action approach intervention (Bottom-up Innovation project)
Number of subjects: 0
Study 23947538 — intervention group
Group type: COMPARATOR
Intervention: Business as usual (control group)
Number of subjects: 0
Study 22011893 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser irradiation at 1.5 W
Number of subjects: 110
Study 22011893 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser irradiation at 3.0 W
Number of subjects: 110
Study 22011893 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-irradiated roots
Number of subjects: 110
Study 22011893 — intervention group
Group type: COMPARATOR
Intervention: Water irrigation
Number of subjects: 110
Study 22011893 — intervention group
Group type: COMPARATOR
Intervention: NaOCl irrigation
Number of subjects: 110
Study 22011893 — intervention group
Group type: COMPARATOR
Intervention: NaOCl/EDTA irrigation
Number of subjects: 110
Study 19277942 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training, 30 Hz, 4 mm amplitude, thrice weekly for 3 min for 4 weeks
Number of subjects: 26
Study 19277942 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 19277942 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training
Number of subjects: 26
Study 16881785 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship enhancing interventions
Number of subjects: 704
Study 16881785 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio and television coverage
Number of subjects: 704
Study 16881785 — intervention group
Group type: EXPERIMENTAL
Intervention: Common selection criteria
Number of subjects: 704
Study 15015704 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 15015704 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 11319936 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-second stretch
Number of subjects: 62
Study 11319936 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second stretch
Number of subjects: 62
Study 11319936 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-second stretch
Number of subjects: 62
Study 11319936 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 62
Study 9226555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast atom bombardment mass spectrometry (FAB‐MS) for urinary and faecal porphyrin analysis
Number of subjects: 0
Study 7959554 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 167
Study 7959554 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative course of chemotherapy and radiotherapy
Number of subjects: 167
Study 2954497 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 0
Study 2954497 — intervention group
Group type: COMPARATOR
Intervention: Clemastine 1 mg twice daily
Number of subjects: 0
Study 2954497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31678343 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day vortioxetine
Number of subjects: 32
Study 31678343 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day vortioxetine
Number of subjects: 32
Study 31678343 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day escitalopram
Number of subjects: 32
Study 31678343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29047178 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 100
Study 29047178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27720136 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus IMA901 (4·13 mg) and granulocyte macrophage colony-stimulating factor (75 μg), with cyclophosphamide (300 mg/m2) 3 days before the first vaccination.
Number of subjects: 339
Study 27720136 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib monotherapy (50 mg orally once daily).
Number of subjects: 339
Study 24925120 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose nuts (50-100 g/d)
Number of subjects: 117
Study 24925120 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose nuts with half-dose muffins
Number of subjects: 117
Study 24925120 — intervention group
Group type: COMPARATOR
Intervention: Full-dose muffins
Number of subjects: 117
Study 24925120 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose nuts
Number of subjects: 117
Study 22133872 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Education and Prelinguistic Milieu Teaching (RPMT)
Number of subjects: 32
Study 22133872 — intervention group
Group type: COMPARATOR
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 32
Study 21234859 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU/day Vitamin E
Number of subjects: 0
Study 21234859 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU/day Vitamin E
Number of subjects: 0
Study 21234859 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IU/day Vitamin E
Number of subjects: 0
Study 21234859 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19076630 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab, 1 mg/kg/week administered subcutaneously for up to 15 months
Number of subjects: 450
Study 16189176 — intervention group
Group type: EXPERIMENTAL
Intervention: GH administration alone
Number of subjects: 7
Study 16189176 — intervention group
Group type: EXPERIMENTAL
Intervention: GH and acipimox co-administration
Number of subjects: 7
Study 16189176 — intervention group
Group type: COMPARATOR
Intervention: Acipimox administration
Number of subjects: 7
Study 16189176 — intervention group
Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 7
Study 14624289 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 300 mg
Number of subjects: 114
Study 14624289 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 25 mg
Number of subjects: 114
Study 10951149 — intervention group
Group type: EXPERIMENTAL
Intervention: Mite allergen avoidance measures (encasing mattresses and pillows; weekly hot wash of bedding; frequent vacuum cleaning; cleaning/removing soft toys and carpets; no pets allowed)
Number of subjects: 41
Study 10951149 — intervention group
Group type: COMPARATOR
Intervention: Allergen avoidance measures (after 12 months for all patients)
Number of subjects: 41
Study 10160375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment (five doses in Sierra Leone, three doses in Nigeria)
Number of subjects: 2436
Study 10160375 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin treatment
Number of subjects: 2436
Study 8296531 — intervention group
Group type: EXPERIMENTAL
Intervention: L-threonine at 6 g/day
Number of subjects: 33
Study 8296531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3711553 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) aqueous spray, 42 mcg per spray
Number of subjects: 44
Study 3711553 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) aerosol spray, 42 mcg per spray
Number of subjects: 44
Study 3711553 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 44
Study 29713137 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicago Parent Program (parent group + video; CPP)
Number of subjects: 159
Study 29713137 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Child Interaction Therapy (individualized mastery‐based coaching; PCIT)
Number of subjects: 159
Study 26763869 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-involved group (FIG)
Number of subjects: 120
Study 24970291 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sepsis patients (T1)
Number of subjects: 60
Study 24970291 — intervention group
Group type: COMPARATOR
Intervention: Control group (T1)
Number of subjects: 60
Study 24970291 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sepsis patients (T2)
Number of subjects: 60
Study 24970291 — intervention group
Group type: COMPARATOR
Intervention: Control group (T2)
Number of subjects: 60
Study 22095945 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-based regimen
Number of subjects: 30
Study 19884812 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy (daily local mud packs and bicarbonate-sulfate mineral bath water) for 2 weeks
Number of subjects: 80
Study 19884812 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine ambulatory care)
Number of subjects: 80
Study 19884812 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy
Number of subjects: 80
Study 18403998 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary-based nurse-led intervention
Number of subjects: 44
Study 16194994 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pre‐warming
Number of subjects: 6
Study 16194994 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive pre‐warming
Number of subjects: 6
Study 16194994 — intervention group
Group type: COMPARATOR
Intervention: Control (pre‐exercise rest)
Number of subjects: 6
Study 12841542 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperprolactinemic patients
Number of subjects: 60
Study 12841542 — intervention group
Group type: COMPARATOR
Intervention: Healthy non‐obese women (control)
Number of subjects: 60
Study 10807894 — intervention group
Group type: EXPERIMENTAL
Intervention: L/MCT diet (equal quantities of LCT and MCT)
Number of subjects: 19
Study 10807894 — intervention group
Group type: COMPARATOR
Intervention: LCT diet (long chain triglycerides)
Number of subjects: 19
Study 8862439 — intervention group
Group type: EXPERIMENTAL
Intervention: 10, 25, 50, or 75 micrograms/kg/day of rhIL-11 administered subcutaneously for 14 consecutive days
Number of subjects: 12
Study 8862439 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11 treatment at the two highest doses
Number of subjects: 12
Study 8862439 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11 treatment
Number of subjects: 12
Study 8862439 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11 therapy at the highest dose
Number of subjects: 12
Study 8862439 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11 administration
Number of subjects: 12
Study 1737653 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute upright leg cycling at 50% of peak aerobic capacity
Number of subjects: 22
Study 1737653 — intervention group
Group type: COMPARATOR
Intervention: 30-minute control period of rest
Number of subjects: 22
Study 4091995 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (200 mg)
Number of subjects: 0
Study 4091995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene/paracetamol mixture (65 mg/650 mg)
Number of subjects: 0
Study 4091995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene/paracetamol mixture (65 mg/650 mg) + Ethanol (0.8 g kg‐1)
Number of subjects: 0
Study 4091995 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.8 g kg‐1)
Number of subjects: 0
Study 4091995 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (200 mg) + Ethanol (0.8 g kg‐1)
Number of subjects: 0
Study 30946121 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection control clinical course for 3 months (experimental group, n = 60)
Number of subjects: 130
Study 30946121 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 70) who did not register for the course
Number of subjects: 130
Study 30211788 — intervention group
Group type: EXPERIMENTAL
Intervention: Single screw fixation (SS)
Number of subjects: 127
Study 30211788 — intervention group
Group type: COMPARATOR
Intervention: Double screw fixation (DS)
Number of subjects: 127
Study 26959509 — intervention group
Group type: EXPERIMENTAL
Intervention: Early limited ART (initiated at/before 12 weeks)
Number of subjects: 38
Study 26959509 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred continuous ART (initiated after 12 weeks)
Number of subjects: 38
Study 26959509 — intervention group
Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 38
Study 24879882 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts wrapped with rectus muscle fascia
Number of subjects: 36
Study 24879882 — intervention group
Group type: COMPARATOR
Intervention: Grafts wrapped with deep temporal fascia
Number of subjects: 36
Study 22710926 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education modules on early feeding practices (2 modules over 3 months)
Number of subjects: 698
Study 22710926 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 698
Study 20194844 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus fludarabine and cyclophosphamide (R-FC)
Number of subjects: 552
Study 20194844 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide alone (FC)
Number of subjects: 552
Study 18815396 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0.9 mg per kilogram of body weight)
Number of subjects: 821
Study 18815396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study 16104444 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine
Number of subjects: 37
Study 16104444 — intervention group
Group type: COMPARATOR
Intervention: Conventional subunit vaccine
Number of subjects: 37
Study 16104444 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 37
Study 12607792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg (for patients weighing <= 30 kg)
Number of subjects: 66
Study 12607792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg (for patients weighing > 30 kg)
Number of subjects: 66
Study 10372608 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 10372608 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 0
Study 10372608 — intervention group
Group type: COMPARATOR
Intervention: Novel antipsychotics (olanzapine, quetiapine, risperidone, sertindole, zotepine)
Number of subjects: 0
Study 7769337 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal warm blood cardioplegia (TWBC)
Number of subjects: 70
Study 7769337 — intervention group
Group type: COMPARATOR
Intervention: No terminal warm blood cardioplegia (Control group II)
Number of subjects: 70
Study 1692948 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg sublingual nifedipine
Number of subjects: 10
Study 1692948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 111940 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 42
Study 111940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 42
Study 111940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 30836031 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0
Study 30836031 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 28129312 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 1 mg
Number of subjects: 32
Study 28129312 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 2 mg
Number of subjects: 32
Study 28129312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25810033 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion programme
Number of subjects: 40
Study 25810033 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 23845629 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced soybean lipid emulsion (1.0 g/kg/day)
Number of subjects: 28
Study 23845629 — intervention group
Group type: COMPARATOR
Intervention: Standard soybean lipid emulsion (3 g/kg/day)
Number of subjects: 28
Study 21107317 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization method for benefit-risk assessment
Number of subjects: 0
Study 21107317 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
Number of subjects: 0
Study 19120324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) - V-beam Perfecta, 595 nm, 0.45-1.5 ms
Number of subjects: 20
Study 19120324 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) - StarLux, Lux G prototype handpiece, 500-670 and 870-1400 nm, 5-10 ms
Number of subjects: 20
Study 17760715 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication (omeprazole, amoxicillin, and clarithromycin)
Number of subjects: 347
Study 17760715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 15601558 — intervention group
Group type: EXPERIMENTAL
Intervention: VmP-WBRT (2 cycles of VmP regimen followed by WBRT)
Number of subjects: 38
Study 15601558 — intervention group
Group type: COMPARATOR
Intervention: WBRT-VmP (WBRT followed by 2 cycles of VmP regimen)
Number of subjects: 38
Study 15601558 — intervention group
Group type: COMPARATOR
Intervention: Control group (WBRT)
Number of subjects: 38
Study 11467764 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 15314
Study 11467764 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 15314
Study 9569998 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-761 (10-160 mg)
Number of subjects: 24
Study 7827746 — intervention group
Group type: EXPERIMENTAL
Intervention: Conforma II mattress overlay
Number of subjects: 30
Study 7827746 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital mattress
Number of subjects: 30
Study 2839724 — intervention group
Group type: EXPERIMENTAL
Intervention: Susta II (12.4-g soy polysaccharide/2000 kcal)
Number of subjects: 14
Study 2839724 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrich (38.5-g soy polysaccharide/2000 kcal)
Number of subjects: 14
Study 2839724 — intervention group
Group type: COMPARATOR
Intervention: Ensure (fiber-free formula)
Number of subjects: 14
Study 1219276 — intervention group
Group type: EXPERIMENTAL
Intervention: Idulian (syrup) 2 x 0.5 mg
Number of subjects: 59
Study 1219276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31201005 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 LVAD
Number of subjects: 0
Study 31201005 — intervention group
Group type: COMPARATOR
Intervention: HVAD
Number of subjects: 0
Study 31201005 — intervention group
Group type: COMPARATOR
Intervention: HeartMate II
Number of subjects: 0
Study 31271239 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcers (monetary rewards for SMBG and associated behaviors)
Number of subjects: 60
Study 31271239 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 60
Study 31271239 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcers
Number of subjects: 60
Study 28710329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (500 mg twice daily, increased to 1,000 mg twice daily after week 2)
Number of subjects: 13